Company Information
Company Profile
Cash Flow Statement
Profit & Loss
Financial Position
Financial Ratio
Industry 制造业
Company Introduction 恒瑞医药创立于1970年，于2000年在上海证券交易所上市，是一家专注研发、生产及推广高品质药物的创新型国际化制药企业，聚焦抗肿瘤、代谢性疾病、自身免疫疾病、呼吸系统疾病、神经系统疾病等领域进行新药研发，是国内最具创新能力的制药龙头企业之一。五十余年来，恒瑞医药始终坚持为患者服务的初心，努力守护患者健康生活和生命质量，攻坚克难推进医药产业高质量发展。在美国制药经理人杂志公布的全球制药企业TOP50榜单中，恒瑞医药已连续5年上榜；在全球医药智库信息平台InformaPharmaIntelligence评选的“全球医药企业研发管线规模TOP25”榜单中，恒瑞医药位列第13位，创中国药企在该榜单的排名新高；中国医药工业信息中心历年发布的“中国医药研发产品线最佳工业企业”，恒瑞医药已11次登顶榜首。用创新守护生命健康——恒瑞医药始终把科技创新作为第一发展战略，持续加码研发，自2011年公司首款创新药获批上市以来，累计研发投入超330亿元，位居全国医药行业前列。公司在连云港、上海、美国和欧洲等地设立14个研发中心，全球研发团队达5000余人。研发投入催生丰硕创新成果，瑞维鲁胺、卡瑞利珠单抗等14款自研1类创新药、4款自研2类新药和2款引进创新药在国内上市，另有80多个自主创新产品正在临床开发，270多项临床试验在国内外开展，形成了上市一批、临床一批、开发一批的良性循环。公司还自主建立了蛋白水解靶向嵌合物（PROTAC）、分子胶、抗体偶联药物（ADC）、双/多特异性抗体、AI分子设计、耐药、体内药理、分子动力学、生物信息等一批国际领先的技术平台，为创新研发提供强大基础保障。让新药、好药惠及更多患者——作为国内医药研发龙头企业，恒瑞医药切实履行企业社会责任，持续提升优质药物的可及性。公司积极支持国家医保惠民举措，已有103个产品陆续进入国家医保目录，其中包括卡瑞利珠单抗、瑞维鲁胺等13款创新药，让国内患者“用得上、用得起”新药、好药。我国首个获批小细胞肺癌适应症的自主研发PD-L1抑制剂阿得贝利单抗上市后不久便被北京、上海等多地纳入“惠民保”，切实减轻患者经济负担。努力推动中国制药品牌走向世界——稳步推进国际化，是恒瑞医药的长期发展战略。目前，公司的医药产品已进入超过40个国家，还在继续加快开拓全球市场并关注新兴市场。公司积极向海外输出创新成果，将卡瑞利珠单抗、吡咯替尼、HRS-1167等多个具有自主知识产权的创新药对海外授权，其中与大型跨国企业默克达成的授权合作，交易总额可达14亿欧元。此外，公司已在欧美日获得包括注射剂、口服制剂和吸入性麻醉剂在内的20多个注册批件，提高了全球不同地区患者的药物可及性。恒心致远，瑞颐人生。恒瑞医药将始终坚持“科技为本，为人类创造健康生活”的使命，以“专注创新，打造跨国制药集团”为愿景，不断强化技术创新主体地位，力争研制出更多的新药、好药，服务“健康中国”，惠及全球患者。
Main Business 药品的研发、生产和销售
Legal Representative 孙飘扬
Top Executives
董事长：孙飘扬
董事：江宁军,郭丛照,孙杰平,戴洪斌,张连山,孙飘扬
独立董事：孙金云,曾庆生,董家鸿
Top 5 Shareholder
Shareholder name Nature Holding Date
江苏恒瑞医药集团有限公司流通A股24.11%30/09/2024
西藏达远企业管理有限公司流通A股14.94%30/09/2024
香港中央结算有限公司流通A股7.05%30/09/2024
中国医药投资有限公司流通A股3.78%30/09/2024
青岛博森泰科技有限公司流通A股2.85%30/09/2024
Company Secretary 刘笑含
Solicitors 北京市浩天律师事务所
Auditors 连云港金衡会计师事务所有限责任公司
Tel No 021-61053323
Fax No 021-61063801
Website www.hengrui.com
Email ir@hengrui.com
Company Address
Register: 江苏省连云港市经济技术开发区黄河路38号
Office: 江苏连云港市经济技术开发区昆仑山路7号
Listing Date 18/10/2000
Shares Capital
Shares Capital: 6,379,002,274
Total A Share: 6,379,002,274
Listed A Share: 6,379,002,274
Non-tradable A Share: 0
Other Share: 0
Total B Share: 0
Total H Share: 0
EPS(RMB)* ¥ 0.680
DPS(RMB)* ¥ 0.200
NBV Per Share(RMB)* ¥ 6.344
Market Capitalization(RMB) 307.914B
Smiley face Only Chinese content is avaliable
N
/
N
 : Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SH-HK Ex-Northbound trade (sell only)
N
/
N
 : Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
* Unadjusted Data
Information provided by: etnet
Terms and Conditions
Risk Disclosure:
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone.
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.